Red Granite Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Red Granite Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	$319K	Sell	6,892 -140	-2%	-$6.14K	0.07%	55
2013 Q2	$314K	Buy	+7,032	New	+$305K	0.08%	51

Other funds holding BMY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LTI

Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Red Granite Advisors's BMY Position: Q3 2013 in Review

Red Granite Advisors reduced its Bristol-Myers Squibb (BMY) stake by 2% in Q3 2013, selling an estimated $6.14K and leaving 6,892 shares worth $319K. The position accounts for 0.07% of the portfolio, ranked #55.

Red Granite Advisors first reported a position in BMY in Q2 2013 and has held it in 2 quarters since. 1,187 funds tracked by Wall St. Rank hold BMY as of Q3 2013.

Red Granite Advisors held 6,892 shares of Bristol-Myers Squibb worth $319K as of Q3 2013.
Red Granite Advisors sold 140 Bristol-Myers Squibb shares in Q3 2013, an estimated $6.14K.
Bristol-Myers Squibb made up 0.07% of Red Granite Advisors's portfolio in Q3 2013, its #55 holding.
Red Granite Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 2 quarters since.
1,187 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2013.

Based on Red Granite Advisors's 13F filing for Q3 2013, filed 6 Nov 2013.